key: cord-0880782-91xxf3l6 authors: Herr, C.; Mang, S.; Mozafari, B.; Guenther, K.; Speer, T.; Seibert, M.; Srikakulam, S. K.; Beisswenger, C.; Ritzmann, F.; Keller, A.; Mueller, R.; Smola, S.; Eisinger, D.; Zemlin, M.; Danziger, G.; Volk, T.; Hoersch, S.; Krawczyk, M.; Lammert, F.; Adams, T.; Wagenpfeil, G.; Kindermann, M.; Marcu, C.; Ataya, Z. W. D.; Mittag, M.; Schwarzkopf, K.; Custodis, F.; Grandt, D.; Schaefer, H.; Eltges, K.; Lepper, P.; Bals, R. title: Distinct patterns of blood cytokines beyond a cytokine storm predict mortality in COVID-19 date: 2021-05-04 journal: nan DOI: 10.1101/2021.05.04.21256497 sha: 77e2985615b09b895746a0983751ff9cfb2f8fe0 doc_id: 880782 cord_uid: 91xxf3l6 Background COVID-19 comprises several severity stages ranging from oligosymptomatic disease to multi-organ failure and fatal outcomes. The mechanisms why COVID-19 is a mild disease in some patients and progresses to a severe multi-organ and often fatal disease with respiratory failure are not known. Biomarkers that predict the course of disease are urgently needed. The aim of this study was to evaluate a large spectrum of established laboratory measurements. Patients and methods Patients from the prospective PULMPOHOM and CORSAAR studies were recruited and comprised 35 patients with COVID-19, 23 with conventional pneumonia, and 28 control patients undergoing elective non-pulmonary surgery. Venous blood was used to measure the serum concentrations of 79 proteins by Luminex multiplex immunoassay technology. Distribution of biomarkers between groups and association with disease severity and outcomes were analyzed. Findings The biomarker profiles between the three groups differed significantly with elevation of specific proteins specific for the respective conditions. Several biomarkers correlated significantly with disease severity and death. Uniform manifold approximation and projection (UMAP) analysis revealed a significant separation of the three disease groups and separated between survivors and deceased patients. Different models were developed to predict mortality based on the baseline measurements of several protein markers. Interpretation Several newly identified blood markers were increased in patients with severe COVID-19 (AAT, EN-RAGE, ICAM-1, myoglobin, SAP, TIMP-1, vWF, decorin, HGF, MMP7, PECAM-1) or in patients that died (FRTN, SCF, TIMP-1, CA-9, CEA, decorin, HGF). The use of established assay technologies allows for rapid translation into clinical practice. Coronavirus disease 2019 (COVID-19) is a novel illness and a rapidly evolving pandemic with large impact on global health. COVID-19 is caused by "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2), a member of the Coronaviridae family that is regarded as a spill-over of an animal coronavirus to humans [1] . [2] or adaptive immunity including activation of type 1 (t-bet, interferon-γ), type-2 (GATA) or type 3 (RORγt, IL-17) immune pathways [3, 4] . Elevation of routine inflammation markers, such as erythrocyte sedimentation rate, Creactive protein (CRP) or procalcitonin (PCT), is frequently but not exclusively observed in the critically ill COVID-19 patient [5] . The term "cytokine storm" has been used to describe the elevation of several acute-phase proteins such as CRP, interleukin-6 (IL-6) or ferritin [6, 7] . Individual markers or patterns have been associated with disease severity or lethality [8] [9] [10] . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 4, 2021. ; https://doi.org/10.1101/2021.05.04.21256497 doi: medRxiv preprint There is a clinical need to identify markers that indicate the risk of disease progression or fatal outcome. The aim of the present study was to identify clinically relevant serum biomarkers from a large spectrum of established laboratory measurements. The marker panel applied in the present study consists of mediators of inflammation and immunity, which are not yet part of clinical routine testing but have been shown to be involved in cellular or humoral immune responses. We measured serum levels of a large panel of cytokines, chemokines, acute phase reactants, growth factors, tissue remodeling enzymes and clinical laboratory parameters in blood samples of hospitalized COVID-19 patients and compared them to control individuals undergoing non-thoracic surgery as well as patients with community-acquired pneumonia. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The present analysis used the baseline data and follow up data of the COVID-19 cohort CORSAAR (n = 35) and its control cohort PULMOHOM, which are multicenter studies focusing on pathomechanisms and the role of risk factors in COVID-19 and other inflammatory lung diseases. Within the PULMOHOM cohort study, 23 patients with pneumonia and 28 control patients undergoing elective non-pulmonary surgery have been included. Patients were recruited at the Saarland University Hospital, the Caritas Klinikum Saarbrücken, the Klinikum Saarbrücken Winterberg, and the SHG-Kliniken Völklingen. The studies have been approved by the ethics committee of the Ärztekammer des Saarlandes, and all patients or their legal representatives gave their informed consent. Basic and anthropomorphic characteristics, the prevalence of comorbidities, and vital parameters were assessed based on measurements, questionnaires, and standardized interviews. Blood samples were drawn after obtaining informed consent from the patient and processed within 4 hours (time-to-centrifugation). Blood was centrifuged for 20 minutes at 2500 g at 4°C in a swing out rotor with break. The serum supernatant was separated immediately after centrifugation under aseptical conditions and transferred into cryo-vials. The vials were integrated into our local biobank (-80°C storage and Biobank Information System (BIMS)) for long term storage. The freezers of the biobank are temperature monitored and access controlled. Upon selection for analysis, the samples were sent on dry ice to the corresponding labs. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 4, 2021. ; https://doi.org/10.1101/2021.05.04.21256497 doi: medRxiv preprint All samples were stored at less than -70°C until tested. Samples were thawed at room temperature, vortexed, spun at 3700 x g for 5 min for clarification and transferred to a master microtiter plate. Using automated pipetting, an aliquot of each sample was added to individual microsphere multiplexes of the selected Multi Analyte Profile (MAP) and blocker. This mixture was thoroughly mixed and incubated at room temperature for 1 hour. Multiplexed cocktails of biotinylated reporter antibodies were added robotically and after thorough mixing, incubated for an additional hour at room temperature. Multiplexes were labelled using an excess of streptavidin-phycoerythrin solution, thoroughly mixed and incubated for 1 hour at room temperature. The volume of each multiplexed reaction was reduced by vacuum filtration and washed thrice. After the final wash, the volume was increased by addition of buffer for analysis using a Luminex instrument and the resulting data interpreted using . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 4, 2021. ; https://doi.org/10.1101/2021.05.04.21256497 doi: medRxiv preprint Continuous variables are presented as mean ± standard deviation when normally distributed or as median (standard deviation). Qualitative variables are presented as absolute and relative frequencies. Statistical differences between three groups considering continuous or categorical variables have been established using oneway Analysis of Variance (ANOVA, assuming normality) with Bonferroni correction as post-hoc test, Kruskal-Wallis test or chi-squared test, respectively. Differences between two groups were analyzed by two-sided T-test. For bivariate correlations, the Pearson's R is reported. A correlation matrix was generated by using R language (version 3.6.1) and plotted using ggplot2 library. For plotting, only the absolute correlation values >0.3 were retained. A linear discriminant analysis was performed to test whether the serum markers identified above can be used to build a model that indicates increased risk of mortality. Neural network analysis (SPPS module multilayer perceptron, MLP, one hidden layer) was performed using "death" as dependent variable and the biomarkers with different serum concentrations in survivors vs. non-survivors as covariates. A two-sided P value of less than 0.05 was considered statistically significant. Statistical analyses were performed using SPSS version 27.0. Dimension reduction and visualization of high dimensional profiles has additionally been carried out using the Uniform Manifold Approximation and Projection (UMAP) by using the R umap package. Input data were z-scaled before computing the UMAP. The number of components was set to 2, and the Euclidean distance was used. The computations for the UMAP used R 4.0.3 GUI 1.73 Catalina build (7892). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 4, 2021. ; The funders of the study had no role in study design, data collection, data interpretation, or writing of the report. The corresponding author had full access to all data in the study and had final responsibility for the decision to submit for publication. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 4, 2021. ; https://doi.org/10.1101/2021.05.04.21256497 doi: medRxiv preprint As a first step we compared the concentrations of blood mediators between patients with pneumonia, COVID-19 and a control group of patients undergoing nonpulmonary surgery. Table 1 summarizes the main characteristics of the patients in these groups and shows that the three groups did not differ with respect to age or body mass index (BMI). Table 1S summarizes the clinical characteristics of all patients. Only male patients were recruited for the control and pneumonia groups to avoid sex-related changes of metabolic parameters. We analyzed the data from the measurements and found that the concentrations of IL-1-alpha, IL-3, IL-4, IL-7, IL-12p70, TNF-beta, and TNF-alpha were below the detection threshold. These markers were excluded from further analysis. Table 2 . Figure 1A displays a selection of markers with significant differences. Comparing COVID-19 to conventional pneumonia revealed significant differences and concentrations of BDNF, MMP-9, and NSE were increased, while A2Macro, B2M, IgA, MIP1alpha, MMP-3, myoglobin, SCF, TNFR2, vWF, AXL, CA-125, CA-9, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 4, 2021. ; https://doi.org/10.1101/2021.05.04.21256497 doi: medRxiv preprint HCC-4, decorin, MMP-7, SPD, TRAIL-R3 were decreased in COVID-19 as compared to pneumonia patients. No significant differences were found for IL-6, or FRTN. As compared to the control group, COVID-19 patients showed increased concentrations of CRP, fibrinogen, IgM, PECAM-1, NSE, AAT, N-RAGE, IL-18, IL-18bp, MCP-1, PAI-1, and SAP. Using a UMAP approach, we classified individuals of all three groups based on their biomarker levels. This procedure resulted in significant segregation of the three groups (Fig. 1B) . COVID-19 is a dynamic disease that often progresses towards respiratory failure and systemic inflammation and shock. The differences of blood concentrations between the disease severity stages (normal care vs. intensive care treatment) were analyzed (Table 3A ). Figure To further evaluate the association between serum markers and disease severity, we measured the ICU scores SAPS II (Simplified Acute Physiology Score) and TISS (Therapeutic intervention scoring system) in COVID-19 patients. Table S2 presents results of bivariate correlation analysis, Figure 2B displays a summary correlation plot. One important goal of the use of biomarkers is to identify patients with increased risk of dying. As no death occurred in the control group and few in the pneumonia group, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 4, 2021. ; https://doi.org/10.1101/2021.05.04.21256497 doi: medRxiv preprint we identified factors associated with mortality only in the COVID-19 group (Table 3B ). Figure 3A displays the significantly changed biomarkers between the survivors and the deceased patients. T-test identified increased levels of eotaxin, FRTN, IL-1beta, IL-1ra, IL-8, IL-10, MCP-1, SCF, TIMP-1, CA-9, CEA, IL-18p. Decreased concentrations were found for albumin, adiponectin, BDNF, and ANG-1. No significant differences were found for BMI or age. A UMAP analysis (Fig. 3B) shows a significant separation between these two groups. A linear discriminant analysis was performed to test whether the serum markers . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 4, 2021. ; https://doi.org/10.1101/2021.05.04.21256497 doi: medRxiv preprint Finally, we performed a ROC analysis and found that IL-1ra, IL-8, IL-10, MCP-1, SCF and CA-9 have an AUC > 0.8. When these variables are subdivided in tertials and a score is established from these data, the AUC is 0.929. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 4, 2021. ; https://doi.org/10.1101/2021.05.04.21256497 doi: medRxiv preprint The main findings of this study are that severe COVID-19 differs from conventional pneumonia by a specific blood cytokine profile. Several serum mediators are correlated with disease severity and outcome. While some blood biomarkers are significantly elevated in severe COVID-19, a classical "cytokine storm" as seen in other conditions was not observed. Several biomarkers are associated with disease severity and risk of death. Blood biomarkers have been used to determine disease severity or risk for deleterious outcome in conventional pneumonia [11] [12] [13] . Biomarkers such as CRP, procalcitonin, and others are important tools for decision making in pneumonia patients. The identification of diagnostic, predictive or prognostic biomarkers is even more relevant in COVID-19. There are two approaches to study the inflammatory processes and to identify biomarkers in COVID-19. One is the application of OMICs technologies to array multiple layers of gene expression, protein and metabolome distribution. A multi-OMICs approach identified patterns that separate mild from severe disease [9] . The combination of transcriptomics, proteomics and metabolomics revealed 219 molecular features related to COVID-19 and linked to complement activation, dysregulated lipid metabolism, and neutrophil activation [4] . A dysregulation of the myeloid cell compartment was found by transcriptomics and single-cell-analysis [2] . The other approach focuses on the measurement of selected biomarkers in clinically relevant cohorts. This approach does not allow a deeper insight into mechanisms but aids to quickly develop clinically relevant information. IL-1RA, IL-10, and RANTES were found to associate with disease severity in a longitudinal investigation [14] . IFN-γ and type I IFN production were found to be relatively deceased, while TNF-α, IL-6, and IL-8 were increased for a prolonged time [15] . The serial analysis of several . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 4, 2021. ; https://doi.org/10.1101/2021.05.04.21256497 doi: medRxiv preprint cytokines in 113 patients showed the early rise in markers to be associated with worse outcome and an activation of type 2 cytokines in severe COVID-19 [3] . Measurement of IL-6, IL-8, TNF-α, and IL-1β were found to be predictive for severity and survival [8] . The measurement of a selected cytokine panel showed that COVID-19 is distinct from conventional pneumonia [7] . In addition to several studies [10, 16] , the present data showed increased serum The term "cytokine storm" in general describes the finding of an exaggerated immune response with excessively elevated cytokine levels and deleterious side effects [6] and it was often highlighted that this phenomenon would be a hallmark of COVID-19. Other reports questioned the role of a cytokine storm in COVID-19 in comparison to other inflammatory conditions [5] . Also, the preset results support this view with . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 4, 2021. ; https://doi.org/10.1101/2021.05.04.21256497 doi: medRxiv preprint COVID-19 patients having a distinct pattern of increased inflammatory mediators but not an out-of-proportion increase. The present study has limitations and strengths: The use of established, rapid multiplex assays allows to translate these findings to validation studies and clinical practice. One important aspect is the direct comparison to non-COVID-19 pneumonia and a control group. The present study has included relatively few COVID-patients and does not cover very mild or asymptomatic individuals nor sequential sampling. Overfitting might be a result of low patient numbers and validation in other cohorts is mandatory. In conclusion, COVID-19 shows a distinct inflammatory blood marker profile separate from conventional pneumonia and extrapulmonary disease. Several markers were associated with disease severity and lethal outcome. We recommend a thorough investigation which of these biomarkers might be causative for immune dysregulation in severe COVID-19 or just a by-product of immune activation. Ideally, proteins strongly connected to COVID-19 pathophysiology could reveal potential targets for immunomodulating therapies for patients at risk. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 4, 2021. ; https://doi.org/10.1101/2021.05.04.21256497 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 4, 2021. ; https://doi.org/10.1101/2021.05.04.21256497 doi: medRxiv preprint Table 2 : Serum concentrations of blood proteins in patients with pneumonia, COVID-19 and control patients without lung disease undergoing elective surgery. Data are median ± SD. * indicates p < 0.05, ** p < 0.005, *** p < 0.001 as calculated using one-way Analysis of Variance (ANOVA, assuming normality) with Bonferroni correction as post-hoc test. The column on the right indicated differences between groups. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 4, 2021. ; https://doi.org/10.1101/2021.05.04.21256497 doi: medRxiv preprint cluster. Following this clustering we computed Fisher's Exact test on the 2x2 contingency table, validating a significant clustering (p < 0.01). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 4, 2021. ; https://doi.org/10.1101/2021.05.04.21256497 doi: medRxiv preprint Coronaviridae Study Group of the International Committee on Taxonomy of V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment Longitudinal analyses reveal immunological misfiring in severe COVID-19 Large-Scale Multi-omic Analysis of COVID-19 Severity Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes Characterization of the Inflammatory Response to Severe COVID-19 Illness An inflammatory cytokine signature predicts COVID-19 severity and survival Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19 Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts German Community Acquired Pneumonia Competence N. Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ Procalcitonin guidance of antibiotic therapy in communityacquired pneumonia: a randomized trial Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison The cytokine storm and COVID-19